261st ENMC International Workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands

Journal article

Adeno-associated virus (AAV) gene therapies are demonstrating much promise in the area of neuromuscular disorders. There are now therapies in clinical trials or real-world use for several disorders including spinal muscular atrophy and Duchenne muscular dystrophy. However, there have been several concerning reports of serious adverse events, including deaths. Reporting and monitoring of these is not consistent between trials. Therefore, a group of clinicians, investigators, industry and patient representatives met the weekend of 17^th–19^th June 2022 to discuss safety issues arising from the use of these therapies. The group shared information on safety events across a spectrum of AAV gene therapy products, both in clinical trials and commercial use. Patterns of serious adverse events were identified and the group discussed methods of identification and management of these as well as new ways of improving information sharing across industry in order to improve the safety of these promising treatments.

Authors: Servais, L; Horton, R; Saade, D; Bonnemann, C; Muntoni, F

• Publication status: Published
• Publisher: Elsevier
• Journal: Neuromuscular Disorders
• Volume: 33
• Issue: 11
• Pages: 884-896
• Publication date: 2023-09-30
• Acceptance date: 2023-09-24
• DOI: 10.1016/j.nmd.2023.09.008
• EISSN: 1873-2364
• ISSN: 0960-8966
• Pmid: 37919208
• Language: English
• Keywords: gene therapy; Duchenne; spinal muscular atrophy; X linked myotubular myopathy; safety; serious adverse event; immunity